Mistletoe is an injectable plant extract used mainly in Europe as an add-on to standard cancer treatment, valued for better day-to-day well-being and generally well tolerated. Reports of improved well-being shrink in the most careful studies, and a survival advantage is not reliably supported. Its realistic value is supportive comfort alongside proven treatment, not replacing it. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Complete blood count with differential | Within normal limits; eosinophils not markedly elevated | Detects immune-response shifts and distinguishes expected reactions from adverse ones |
| Eosinophil count | Mild transient rise acceptable; not persistently high | Tracks the immune activation thought to drive effects |
| C-reactive protein (CRP) | Low (<1 mg/L optimal) | Helps separate treatment-related inflammation from infection or progression |
| Liver enzymes (ALT, AST) | Within normal limits | Screens for any systemic toxicity during prolonged use |
| Tumor markers / imaging (per cancer type) | Stable or improving per oncologist | Tracks actual disease control, the ultimate success measure |
| Body temperature | Afebrile at baseline; transient low-grade fever expected post-dose | Guides whether to proceed with or defer a scheduled dose |
Cadence: Baseline before first dose, then every 1–2 weeks during dose escalation, then every 1–3 months while on therapy